A growing body of evidence indicates that resolution of acute inflammation is an active process 1, 2 . Resolvins are a new family of lipid mediators enzymatically generated within resolution networks that possess unique and specific functions to orchestrate catabasis, the phase in which disease declines 2, 3 . Resolvin D2 (RvD2) was originally identified in resolving exudates, yet its individual contribution in resolution remained to be elucidated. Here, we establish RvD2's potent stereoselective actions in reducing excessive neutrophil trafficking to inflammatory loci. RvD2 decreased leukocyteendothelial interactions in vivo by endothelial-dependent nitric oxide production, and by direct modulation of leukocyte adhesion receptor expression. In mice with microbial sepsis initiated by caecal ligation and puncture, RvD2 sharply decreased both local and systemic bacterial burden, excessive cytokine production and neutrophil recruitment, while increasing peritoneal mononuclear cells and macrophage phagocytosis. These multi-level pro-resolving actions of RvD2 translate to increased survival from sepsis induced by caecal ligation and puncture and surgery. Together, these results identify RvD2 as a potent endogenous regulator of excessive inflammatory responses that acts via multiple cellular targets to stimulate resolution and preserve immune vigilance.
Ungoverned inflammation is an underlying component of many pathologies, such as cardiovascular disease, diabetes and sepsis 4, 5 . It's now recognized that resolution of inflammation is an active programme controlled by temporal and spatial production of specialized chemical mediators 2, 3, 6 . Recently, autacoids endogenously generated from omega-3 essential fatty acids, namely resolvins, were identified during the resolution phase of inflammation that actively promote catabasis via potent pro-resolving and anti-inflammatory actions 2, 3 . RvD2, biosynthesized from docosahexaenoic acid (DHA), was originally identified during resolution 3 . Its complete stereochemistry and actions remained of interest. To this end, we investigated whether RvD2 preserves host immune function to facilitate resolution of inflammatory sepsis.
First, the complete stereochemistry of endogenous RvD2 was determined by physical matching with compounds prepared by total organic synthesis ( Supplementary Fig. 1a ) from enantiomerically and geometrically pure starting materials in accordance with the basic structure determined in resolving exudates 3 (Fig. 1 ). This approach was needed because the nanogram amounts of endogenous RvD2 isolated precluded direct nuclear magnetic resonance (NMR) analysis. The double-bond geometry of synthetic material was validated by 1 H NMR ( Supplementary Fig. 1b ). The biosynthesis of RvD2 involves 17-lipoxygenation of DHA to 17S-hydroperoxy-4Z, 7Z, 10Z, 13Z, 15E, 19Z-docosahexaenoic acid , which is enzymatically transformed to a 7(8)epoxide-containing intermediate 3, 7 in human leukocytes. This enzymatic activity involves 5-lipoxygenase (LOX) and its epoxide-generating activity 8 . These steps can occur within a single cell type or via transcellular biosynthesis. For example, eosinophils, rich in 15-LOX, can convert DHA to 17-HpDHA, which polymorphonuclear neutrophils (PMNs) can convert to RvD2 (Fig. 1a ). Actively phagocytosing PMNs converted resolvin precursor 17-HpDHA to RvD2 as determined by lipidomics based on liquidchromatography tandem mass spectrometry (LC-MS/MS). A total ion chromatogram (mass-to-charge ratio m/z 5 375 [M-H]) of human leukocyte-derived RvD2 is shown ( Fig. 1b) , with characteristic conjugated tetraene ultraviolet (UV)-chromophore (absorbance l max at 301 nm with shoulders at 289 nm and 315 nm). Synthetic material showed an exclusive and prominent peak with retention time and UV spectrum essentially identical to leukocyte-derived RvD2 (Fig. 1c ). Co-injection of synthetic and leukocyte-derived RvD2 led to an increase in intensity and co-elution ( Fig. 1d ). To further establish the physical properties, their tandem mass spectra were analysed, with essentially identical mass spectrum, and diagnostic ions in agreement with original assignments for endogenous RvD2 (Fig. 1e , f) 3 . To validate the biosynthetic pathway, activated human PMNs were incubated with deuterium-labelled 17S-HpDHA-d 5 or DHA-d 5 ; RvD2 containing the d5 label was biosynthesized ( Fig. 1g ), the parent ion [M-H] increased to m/z 380, and neutral loss ions reflective of d5-containing fragments ( Supplementary Fig. 2 ). Next, to further confirm the structural assignment 3, 9 , derivatized RvD2 was subjected to gas chromatography-mass spectrometry (GC/MS). The derivatized RvD2 C-value was 25.2 6 0.1 and its spectrum ( Supplementary Fig. 3 ) showed diagnostic ions at m/z 479, 435, 229 and 171 (see ref. 3) . Collectively, matching of synthetic and leukocyte-derived RvD2 (by retention time, mass spectral diagnostic ions and derivatization) established the complete stereochemistry and double-bond geometry of endogenous RvD2 as 7S, 16R, 17S-trihydroxy-4Z, 8E, 10Z, 12E, 14E, 19Z-docosahexaenoic acid.
RvD2 displayed potent actions in microbial peritonitis, with a drastic ,70% reduction in zymosan-stimulated PMN infiltration at doses as low as 10 pg (Fig. 2) . Importantly, the D10-trans-RvD2 isomer was essentially inactive, indicating that specific geometry of endogenous RvD2 is required for bioactivity. To determine whether RvD2 decreases leukocyte-endothelial interactions, microcirculation in the cremaster muscle was analysed. Platelet activating factor (PAF; 100 nM) 6,10 superfusion caused increased leukocyte adherence and emigration that was markedly reduced by 1 nM RvD2 (Fig. 2c, d ). Representative microcirculation before and after RvD2 superfusion is shown in the Supplementary movies. These potent RvD2 actions were recapitulated with human cells to identify potential cellular directed actions (that is, endothelial cells and PMN). RvD2 potently reduced PAF-stimulated capture and adhesion of PMN by human umbilical vein endothelial cells (HUVECs) under flow ( Supplementary Fig. 4 ) 11 . We note that RvD2 also reduced complement-mediated (with complement C5a) PMN-endothelial interactions ( Supplementary Fig. 5a -c), a key mediator in sepsis 12 . Consistent with the impact of RvD2 on leukocyteendothelial interactions, RvD2 diminished PAF-stimulated CD62L (L-selectin) shedding on isolated human PMN, and CD18 (ITGB2 , also known as integrin beta 2) surface expression ( Fig. 2e , f). RvD2 alone did not alter PMN adhesion molecule expression (n 5 3, not shown). To obtain further evidence for direct actions of RvD2 on human leukocytes, we monitored reactive oxygen species (ROS) . Importantly, RvD2 did not stimulate extracellular superoxide, and it potently reduced C5a-stimulated extracellular superoxide generation (see below and Supplementary Fig. 5e , f).
Next, we assessed the contribution of nitric oxide, an established antiadhesive mediator 13, 14 in RvD2-reduced leukocyte adherence in postcapillary venules. The non-selective nitric oxide synthase inhibitor L-NAME, before addition of RvD2, partially reversed the decreased leukocyte adherence and emigration ( Fig. 3a, b ). To obtain additional evidence for nitric oxide generation by RvD2 in vivo, vascular fluorescence was monitored (see Methods). Topical administration of RvD2 (100 pg per ear) increased fluorescence intensity, whereas lower doses (1 pg and 10 pg) were ineffective ( Supplementary Fig. 6a ). L-NAME given before topical RvD2 application abolished this response (Supplementary Fig. 6b ), indicating that RvD2-stimulated vascular responses at this dose were nitric-oxide-dependent. We note that intravenous injection of RvD2 at doses that inhibited PMN infiltration in peritonitis (10 pg) did not increase fluorescence intensity, indicating that only local elevated doses of RvD2 stimulated vascular responses (not shown). Additionally, RvD2 superfusion (1 nM) did not cause an increase in vascular permeability ( Supplementary Fig. 6e ). Topical RvD2 (10 pg or 100 pg) did not induce leukocyte infiltration into ear skin compared to chemoattractant leukotriene B 4 ( Supplementary Fig. 6f ). These results demonstrate that high focal delivery of RvD2 stimulates rapid nitric oxide production consistent with its anti-adhesive effects but not to a level that is pro-inflammatory.
Corroboratory results were obtained with HUVECs whereby RvD2 dose-dependently stimulated nitric oxide generation ( Fig. 3c ), suggesting that topical actions were probably mediated via endothelial nitric oxide synthase (eNOS). To test this, peritonitis was evaluated in mice deficient in eNOS. In agreement with an earlier report 15 , no changes were observed with respect to leukocyte infiltration between wild-type and eNOS 2/2 (also known as Nos3 2/2 ) mice. RvD2 reduction in leukocytes was eliminated in eNOS 2/2 mice ( Fig. 3d ), an effect that has also been reported for aspirin and local aspirin-triggered lipoxins 16 . Notably, RvD2 also stimulated vasoprotective prostacyclin (6-keto-PGF 1a ; Supplementary Fig. 7a ); this dose-response curve proved to be bellshaped like other lipid mediators 1,2,6 . RvD2-stimulated prostacyclin and nitric oxide were sensitive to pertussis toxin, implicating a role for G-protein coupled receptor(s) ( Supplementary Fig. 7b, c) . Thus, RvD2 regulates leukocyte adherence via both direct actions on PMN (see above) and endothelial vasoactive substances.
Next, anti-inflammatory and pro-resolving actions of RvD2 were evaluated in caecal ligation and puncture (CLP), an established murine microbial sepsis that closely resembles human pathology 17, 18 . Omega-3 fatty acids are beneficial in some inflammatory conditions, including sepsis [19] [20] [21] , although the mechanistic basis underlying protection is still emerging. Indeed, RvD2 significantly reduced the amount of live aerobic bacteria in both blood and peritoneum at 12 h post-CLP, whereas D10-trans-RvD2 was essentially not active ( Fig. 4a, b ). This was associated with a significant reduction in total leukocytes and specifically, PMN infiltration into the peritoneum (Fig. 4c, d) . Interestingly, the ratio of mononuclear cells to PMN was increased with RvD2 ( Fig. 4d, inset) , similar to results obtained with sterile zymosan-stimulated peritonitis ( Supplementary Fig. 9a ). Intraperitoneal delivery of RvD2 at 1 h post-CLP also reduced both blood and peritoneal bacteria ( Supplementary Fig. 8 ). Macrophages have an important role in the clearance of bacteria, cellular debris and apoptotic PMNs to facilitate inflammation resolution 1,2 . RvD2 treatment promoted phagocyte-dependent bacterial clearance observed in inguinal lymph nodes ( Supplementary Fig. 10d ). Evidence for direct macrophage actions were obtained in vitro, where RvD2 potently enhanced macrophage phagocytosis of opsonized-zymosan (Supplementary Fig. 9b ).
To obtain additional evidence for this pro-resolution role of RvD2, cytokines were monitored during CLP both locally (peritoneum) and systemically (plasma). RvD2 drastically reduced levels of pro-inflammatory cytokines associated with poor outcomes in sepsis 18 , namely the interleukins IL-6, IL-1b, IL-23 and tumour necrosis factor TNF-a ( Fig. 4e and Supplementary Fig. 10a ). RvD2 reduced cytokine levels while enhancing bacterial clearance, a response also observed for macrophage scavenger receptor A 22 . Hence, it LETTERS is plausible that RvD2 prevents persistent amplification signals downstream of pattern-recognition receptors, dampening the responses of classically activated macrophages 23, 24 . RvD2 also drastically decreased IL-17, as well as IL-10, which is of interest because of its detrimental impact on survival in sepsis 25 . Thus, RvD2 differs in action from lipoxin A 4 , which stimulates IL-10 (ref. 26) . High levels of both pro-and anti-inflammatory cytokines, including IL-10, are predictive of early mortality in sepsis, and diminishing IL-10 levels proved beneficial in sepsis 27, 28 . Pro-inflammatory mediators, including prostaglandin E 2 (PGE 2 ) and LTB 4 , were also decreased in peritoneum by RvD2 (Fig. 4f, g and Supplementary  Fig. 10b, c) . Interestingly, in addition to macrophage-directed actions, RvD2 directly enhanced PMN Escherichia coli phagocytosis that was accompanied by an increase in intracellular ROS (Fig. 4h, i) . RvD2 does not possess direct antibacterial activity compared to ampicillin ( Supplementary Fig. 11 ). RvD2-treated CLP mice also showed protection at 12 h post-CLP from hypothermia (Fig. 4j) . Accordingly, RvD2 dramatically increased survival rates among CLP-operated mice (Fig. 4k ) and activity levels 12 h post-CLP were resumed (Supplementary movie 3).
The present results establish the complete stereochemistry of endogenous RvD2 and its potent stereoselective actions facilitating resolution. Local and systemic bacterial burden in microbial sepsis were controlled and significantly dampened with RvD2. This potent D-series resolvin protected CLP-mice from excessive leukocyte infiltration and overzealous cytokine production, and also enhanced clearance of microbes, thus preventing sepsis-induced lethality. Sepsis remains a clinical challenge, with high mortality rates and increasing prevalence 5, 29 . Given the uncontrolled inflammatory pathogenesis of sepsis, anti-inflammatory therapies are used for sepsis management in humans, but have ultimately failed owing primarily to sustained immunosuppression 5 . Overall, these results indicate that RvD2 is a potent endogenous mediator which actively promotes the resolution of inflammation, suggesting new therapeutic approaches that do not compromise host defence. Animals, Scientific Procedures Act, 1986). Intra-vital microscopy was used to observe actions of RvD2 on leukocyte responses stimulated by PAF (100 nM C16 form C 26 H 54 NO 7 P; Sigma; PAF administered 1 h before RvD2 was given at time 0) within the cremasteric microcirculation of C57 BL/6 mice. Mice were anaesthetized with xylazine (7.5 mg kg 21 ) and ketamine (150 mg kg 21 ), and cremaster prepared 30 . In some experiments, fluorescein isothiocyanate (FITC)-albumin (1 mg) was administered intravenously to assess vascular leakage. Caecal ligation and puncture. CLP was performed in male FVB mice 17 , in accordance with the Harvard Medical Area Standing Committee On Animals Protocol #02570. The caecum was ligated below the ileocaecal valve for midgrade sepsis 17 . A through and through puncture was performed with a 20-gauge needle, followed by one additional puncture in the distal tip of the caecum. Mice received saline (500 ml subcutaneously) followed by intravenous administration of vehicle (0.1% ethanol), or RvD2 methyl ester (100 ng) at the time of puncture.
METHODS SUMMARY
In some experiments, RvD2-Me (1 mg) was administered intraperitoneally 1 h post-CLP. At 12 h, rectal temperature was measured, blood collected by cardiac puncture and peritoneal exudates obtained. Blood and peritoneal bacteria levels were determined by growth on tryptic soy agar plates. Plasma and peritoneal cytokine levels were determined by Searchlight array. Peritoneal cells were differentiated using Wright-Giemsa staining.
Statistics. Data are mean 6 s.e.m. Multiple group comparisons were made using one-way or two-way analysis of variance (ANOVA) followed by Dunnett's or Bonferroni post tests where appropriate and direct comparisons made using a two-tailed unpaired Student's t-test. Kaplan-Meier survival curves were analysed using a one-tailed log-rank test. In all cases, a P value ,0.05 was considered significant.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
RvD2 total organic synthesis. Total organic synthesis of RvD2 will be reported elsewhere. Briefly, stereochemically pure RvD2 methyl ester was prepared using chiral starting materials having the same stereochemistry of the three OH groups and using stereochemically controlled processes ( Supplementary Fig. 1a ). Thus, the synthesis started with the nucleophilic opening of enantiomerically pure protected glycidol 1 with a protected derivative of pentynoic acid 2, followed by functional group manipulations to form intermediate 3. Synthesis of the intermediate that contains the 16,17-diol moiety was prepared starting with a protected form of 2-deoxyribose 4, which was converted to intermediate 5 using a Wittig reaction that selectively formed a C 5 C bond with a Z-geometry. Conversion of 5 to alkyne intermediate 6, followed by palladium-mediated Sonogashira coupling of 6 with iodide 3 gave compound 7, the acetylenic precursor of RvD2. Removal of the protective groups and selective hydrogenation to convert the alkyne moiety to a C 5 C bond with a Z-geometry gave the RvD2 methyl ester (RvD2-Me). This compound was purified by high-performance liquid chromatography (HPLC) and fully characterized with NMR spectroscopy and mass spectrometry ( Supplementary Fig. 1 and Fig. 1c and f) . This is a different synthetic strategy for RvD2 than reported in ref. 9 . The D10-trans-RvD2 was prepared by isomerization at room temperature (21 uC) and exposure to light overnight, and was isolated using reverse phase (RP)-HPLC before bioassay. . Criteria for identification were: liquid chromatography retention time and a minimum of six fragment diagnostic ions on the MS/MS spectrum matching those of synthetic standards. Deuterated 5S-HETE (Cayman Chemicals, 2 ng) was added before extraction as internal standard for recovery calculations. Murine peritonitis and macrophage phagocytosis. Peritonitis was assessed using male FVB mice (Charles River) or eNOS 2/2 mice and their wild-type littermates (C57BL/6J; Jackson Labs). Vehicle (1.0% EtOH) or RvD2 (0.001-100 ng per mouse) were administered intravenously followed by intraperitoneal administration of zymosan A (1 mg; Sigma). Peritoneal lavages were collected after 4 h and leukocyte infiltration was assessed by light microscopy, followed by differential analysis using Wright-Giemsa staining. For macrophage phagocytosis, resident peritoneal macrophages were harvested from naive mice and incubated with RvD2 (0.01-100 nM) for 15 min at 37 uC before the addition of opsonized FITC-labelled zymosan. After 30 min, extracellular fluorescence was quenched by trypan blue and fluorescence was determined using a Victor3 plate reader (PerkinElmer). Direct actions of RvD2 on human endothelial cells and PMN. Primary HUVECs (Lonza) were incubated with or without pertussis toxin (100 ng ml 21 ,
